These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27650498)

  • 1. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
    Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
    J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.
    Sahni JM; Gayle SS; Webb BM; Weber-Bonk KL; Seachrist DD; Singh S; Sizemore ST; Restrepo NA; Bebek G; Scacheri PC; Varadan V; Summers MK; Keri RA
    Cancer Res; 2017 Oct; 77(19):5395-5408. PubMed ID: 28807940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
    Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
    Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
    EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.
    Ren C; Zhang G; Han F; Fu S; Cao Y; Zhang F; Zhang Q; Meslamani J; Xu Y; Ji D; Cao L; Zhou Q; Cheung KL; Sharma R; Babault N; Yi Z; Zhang W; Walsh MJ; Zeng L; Zhou MM
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7949-7954. PubMed ID: 30012592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells.
    Xu JL; Yuan YJ; Lv J; Qi D; Wu MD; Lan J; Liu SN; Yang Y; Zhai J; Jiang HM
    J Cell Mol Med; 2020 Nov; 24(22):13036-13045. PubMed ID: 32954665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
    Tentler JJ; Ionkina AA; Tan AC; Newton TP; Pitts TM; Glogowska MJ; Kabos P; Sartorius CA; Sullivan KD; Espinosa JM; Eckhardt SG; Diamond JR
    Mol Cancer Ther; 2015 May; 14(5):1117-29. PubMed ID: 25758253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
    Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
    J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
    Kawai M; Nakashima A; Kamada S; Kikkawa U
    J Biomed Sci; 2015 Jul; 22(1):48. PubMed ID: 26141684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
    Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
    Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 19. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
    Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.